Role of DW-MRI and ADC value in monitoring therapy of head and neck squamous cell carcinoma

Aim: To evaluate role of DW-MRI and ADC value in monitoring therapy of head and neck squamous cell carcinoma (HNSCC). Patients & methods: Fourty patients with head and neck squamous cell carcinoma, age ranged from 40 to 68 years, 30 patients were male while 10 were female. Pre-treatment examinat...

Full description

Bibliographic Details
Main Authors: Hosny Saied A. Ghany, Manal Fayez Abu Samra, May El-Saieed, Amany Saber Gerges, Ebtesam Ismaiel Hasan, Ahmed Abdel Rahman, Nisreen D.M. Toni
Format: Article
Language:English
Published: SpringerOpen 2018-12-01
Series:The Egyptian Journal of Radiology and Nuclear Medicine
Online Access:http://www.sciencedirect.com/science/article/pii/S0378603X18301797
Description
Summary:Aim: To evaluate role of DW-MRI and ADC value in monitoring therapy of head and neck squamous cell carcinoma (HNSCC). Patients & methods: Fourty patients with head and neck squamous cell carcinoma, age ranged from 40 to 68 years, 30 patients were male while 10 were female. Pre-treatment examinations included contrast-enhanced CT, endoscopic biopsy & MRI study. Pre-treatment 1st DW-MRI imaging within 10 days before treatment (ADC1), 2nd imaging 3 weeks after start of treatment (ADC2) and 3rd after 6–8 weeks from end of treatment. Results: Significant changes between mean ADC value of 40 primary lesions & 22 metastatic LNs, noted at ADC1 and ADC2, indicating high ability of DW-MRI to detect early changes occur after beginning of treatment. Relationship between pretreatment ADC value and prediction of early treatment response revealed 76.9% sensitivity, 71.4% specificity, 83.3% PPV and 62.5% NPV. ROC curve for fractional ADC value change (ADC2 - ADC1) from 40 lesions primary tumors provided best discriminatory accuracy (AUC = 0.85 ± 0.09) in distinguishing between responders and non-responders with 92.3% sensitivity, 85.7% specificity, 92.9% PPV and 85.7% NPV. Conclusion: Intra treatment ADC value can be used as a marker for prediction and monitoring therapy response for HNSCC. Keywords: ADC, Monitoring therapy, HNSCC
ISSN:0378-603X